Marquette University

e-Publications@Marquette
Biomedical Sciences Faculty Research and
Publications

Biomedical Sciences, Department of

8-2011

Natural and Synthetic Corticosteroids Inhibit Uptake2-Mediated
Transport in CNS Neurons
Jonathan E. Hill
Marquette University

Khadijah Makky
Marquette University, khadijah.makky@marquette.edu

Lalita Shrestha
Marquette University

Cecilia J. Hillard
Medical College of Wisconsin

Paul J. Gasser
Marquette University, paul.gasser@marquette.edu

Follow this and additional works at: https://epublications.marquette.edu/biomedsci_fac
Part of the Neurosciences Commons

Recommended Citation
Hill, Jonathan E.; Makky, Khadijah; Shrestha, Lalita; Hillard, Cecilia J.; and Gasser, Paul J., "Natural and
Synthetic Corticosteroids Inhibit Uptake2-Mediated Transport in CNS Neurons" (2011). Biomedical

Sciences Faculty Research and Publications. 37.
https://epublications.marquette.edu/biomedsci_fac/37

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Natural and Synthetic
Corticosteroids Inhibit Uptake2Mediated Transport in CNS Neurons

Jonathan E. Hill
Department of Biomedical Sciences, Marquette University
Milwaukee, WI

Khadijah Makky
Department of Biomedical Sciences, Marquette University
Milwaukee, WI

Lalita Shrestha
Department of Pharmacology & Toxicology, Medical College of
Wisconsin
Milwaukee, WI

Cecilia J. Hillard
Department of Pharmacology & Toxicology, Medical College of
Wisconsin
Milwaukee, WI

Paul J. Gasser
Department of Biomedical Sciences, Marquette University
Milwaukee, WI

Physiology & Behavior, Vol. 104, No. 2 (August 2011): pg. 306-311. DOI. This article is © Elsevier and permission has been
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Elsevier.

1

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Abstract: In addition to exerting actions via mineralocorticoid and
glucocorticoid receptors, corticosteroids also act by inhibiting uptake2, a highcapacity monoamine transport system originally described in peripheral
tissues. Recent studies have demonstrated that uptake2 transporters are
expressed in the brain and play roles in monoamine clearance, suggesting
that they mediate some corticosteroid effects on physiological and behavioral
processes. However, the sensitivity of brain uptake2 to many natural and
synthetic corticosteroids has not been characterized. Cultured rat cerebellar
granule neurons (CGNs) were previously shown to exhibit corticosteronesensitive accumulation of the uptake2 substrate1-methyl-4-phenylpyridinium
(MPP+). We examined the expression of uptake1 and uptake2 transporters in
CGNs, and tested the effects of a variety of natural and synthetic
corticosteroids on accumulation of [3H]-MPP+ by these cells. Cultured rat
CGNs expressed mRNA for three uptake2-like transporters: organic cation
transporters 1 and 3, and the plasma membrane monoamine transporter.
They did not express mRNA for the dopamine or norepinephrine transporters,
and expressed very little mRNA for the serotonin reuptake transporter.
Accumulation of [3H]-MPP+ by CGNs was dose-dependently inhibited by
corticosterone and decynium-22, known inhibitors of uptake2. Accumulation of
MPP+ was also dose-dependently inhibited, with varying efficacies, by
aldosterone, 11-deoxycorticosterone, cortisol, and cortisone, and by the
synthetic glucocorticoids betamethasone, dexamethasone and prednisolone,
and the glucocorticoid receptor antagonist RU38486. These studies
demonstrate that uptake2 in the CNS is inhibited by a variety
of natural and synthetic corticosteroids, and suggest that inhibition of
uptake2-mediated monoamine clearance may underlie some behavioral and
physiological effects of these hormones.
Keywords: brain, glucocorticoid, mineralocorticoid, monoamine, transport,
non-genomic

1. Introduction
Natural and synthetic corticosteroids are powerful modulators of
neuronal physiology and behavior. By actions at a variety of cellular
targets, they initiate both rapid and delayed effects on central nervous
system (CNS) function. Recent studies suggest that, in addition to
exerting actions via the mineralocorticoid and glucocorticoid receptors
(MR and GR), corticosteroids also act by inhibiting monoamine
clearance mediated by uptake2, a high-capacity, low-affinity transport
system for norepinephrine, epinephrine, dopamine, histamine and
serotonin [1-4]. In contrast to uptake1, which is mediated by a
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combination of the specific transporters for norepinephrine (NET),
dopamine (DAT), and serotonin (SERT), uptake2 is a higher-capacity
but lower affinity transport system, and is acutely inhibited by
corticosterone and other steroids [5, 6]. Inhibition of uptake2 in
cardiac or smooth muscle tissue by acute bath application of
corticosteroids enhances the contractile effects of exogenously applied
epinephrine, norepinephrine, serotonin and histamine [7-12]. Recent
studies have identified a small group of transporters that mediate
uptake2-like transport and have demonstrated their expression in the
brain [3, 4, 13-15]. Thus, uptake2 is a mechanism by which
corticosteroids may act to enhance the actions of monoamines in the
CNS as well as in peripheral targets.
Uptake2 activity has been attributed to a group of broadlyspecific organic cation transporters. These include the organic cation
transporter (OCT) family: OCTs 1, 2 and 3, and the plasma membrane
monoamine transporter (PMAT). Because OCT3 is the most sensitive of
these transporters to inhibition by corticosterone, it has been
described as the most important uptake2 transporter[16-18]. However,
all of the above transporters have uptake2-like characteristics. All are
broadly-specific organic cation transporters, capable of transporting,
with varying efficiencies, norepinephrine, epinephrine, serotonin,
dopamine and histamine, as well as the cationic neurotoxin 1-methyl4-phenylpyridinium (MPP+) [13, 16, 19, 20]. All are sensitive to
inhibition by corticosterone, though their sensitivities differ widely [3,
13, 17, 18, 21, 22], and all are inhibited by the pseudoisocyanine
compound 1, 1’-diethyl-2, 2’-cyanine iodide
(decynium-22) [13, 23].
All of the uptake2 transporters are expressed, at varying levels
and with distinct distributions, in rodent and human brain [3, 4, 1315], and recent studies suggest that they play important roles in
monoamine clearance. Pharmacological inhibition of uptake2 by direct
application of decynium-22 decreases the rate of serotonin clearance
in mouse hippocampus [1], and treatment of rats with the OCT3
inhibitor normetanephrine potentiates venlafaxine-induced increases in
extracellular norepinephrine concentrations in rat prefrontal cortex
[24]. Extracellular concentrations of dopamine are elevated in the
striatum of OCT3 knockout mice [25]. These studies demonstrate that
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uptake2 transporters play important roles in regulating extracellular
concentrations of monoamines in the rodent brain.
Each of the identified uptake2-like transporters is inhibited by
corticosterone, though they differ in their sensitivity to this
corticosteroid. OCT3 is the most sensitive (IC50 = 0.04 – 0.2 μM),
followed by OCT2 (IC50 = 4 μM), OCT1 (IC50 = 150 μM) and PMAT (Ki
= 450 μM) [3, 13, 17, 18, 21, 22]. Studies in peripheral tissues
suggest that uptake2-mediated transport is also inhibited by a variety
of natural and synthetic corticosteroids. In vascular smooth muscle,
the mineralocorticoids aldosterone and 11-deoxycorticosterone
enhance the contractile effects of epinephrine [26, 27], and OCT3mediated norepinephrine clearance in bronchial smooth muscle is
inhibited by the synthetic corticosteroids budesonide,
methylprednisolone, and fluticasone [28]. These studies suggest that
uptake2 inhibition may play an important role in mediating the effects
of both natural and synthetic corticosteroids on neuronal physiology
and behavior.
Given the powerful behavioral effects attributed to a wide
variety of both natural and synthetic corticosteroids, it is important to
understand the potential contribution of uptake2 inhibition to their
actions in the CNS. However, the structure activity relationships
among the natural and synthetic corticosteroids for inhibition of
uptake2 in neurons have not been determined. We recently
demonstrated that rat cerebellar granule neurons (CGNs) in culture
accumulate [3H]-MPP+ in a corticosterone-sensitive manner, and that
they express the uptake2 transporter OCT3, but not the uptake1
transporter DAT [29]. In the present studies, we fully characterized
the expression of uptake1 and uptake2 transporters in CGNs, and
examined the sensitivity of uptake2-mediated accumulation of [3H]MPP+ to various natural and synthetic corticosteroid hormones. This
information is important for a full understanding of the mechanisms by
which corticosteroids influence CNS function.
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2. Materials and methods
2.1. Materials
All steroids were purchased from Steraloids (Newport, RI).
Timed pregnant female Sprague-Dawley rats were purchased from
Harlan (Madison, WI). 1-[3H]-Methyl-4-phenylpyridinium ([3H]MPP+) (specific activity of 86.4 Ci/mol) was purchased from Perkin
Elmer (Waltham, MA). Primers for RT-PCR were synthesized by
Invitrogen (Carlsbad, CA).

2.2. Culture of cerebellar granule neurons
CGNs were prepared from 6-8-day-old rat pups of either sex as
described previously [30] except that cerebellae were incubated in 40
rather than 20 U/mL of papain. Cells were plated onto 6-well culture
plates (2 ml, 1x106 cells/mL) and were maintained in basal minimal
Eagle’s media (BME; Invitrogen) supplemented with 10% heatinactivated fetal bovine serum, 25 mM KCl, 5 mM glutamine, and 0.01
mg/ml ampicillin. After 24 h, cytosine arabinoside (10 μM) was added
to the cultures to inhibit glial proliferation. After 5 days in culture, 600
μl of the media was removed and replaced with BME supplemented as
above, except that B-27 (Invitrogen) was substituted for fetal bovine
serum.

2.3. [3H]-MPP+ uptake assay
Uptake experiments were carried out at room temperature on
CGNs that had been in culture for 6-8 days. Cells were washed and
pre-incubated in 1.8 mL transport buffer (25 mM Tris Base, pH 8.5,
280 mM mannitol, 5.4 mM KCL, 1.8 mM CaCl2, 0.8 mM MgSO4 and 5
mM glucose). To test the effects of putative uptake2 inhibitors on MPP+
accumulation, CGNs were incubated in the presence of vehicle or
increasing concentrations of inhibitors for 5 minutes before the
addition of 20 nM [3H]-MPP+. Uptake was terminated after two minutes
by aspiration of transport buffer, followed by two washes with 1mL
icecold transport buffer. CGNs were lysed by scraping in 500 μl water.
Radioactivity in the cell lysate was determined by liquid scintillation
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spectroscopy. Uptake experiments were repeated at least three times,
except where noted. The effects of the following inhibitors were
tested: 11-dehydrocorticosterone (10 nM – 5.0 μM); 11deoxycorticosterone (10 nM- 1 μM); aldosterone (10 nM – 1 μM);
betamethasone (10 nM – 1 μM); corticosterone (10 nM – 5 μM);
cortisol (10 nM – 10 μM); cortisone (10 nM – 5 μM); decynium-22
(0.01 nM – 0.1 μM); dexamethasone (0.1 nM – 1 μM); prednisolone
(10 nM – 5 μM); RU38486 (10 nM – 5 μM).

2.4. Reverse transcriptase-PCR
After 7 days in culture, CGNs were washed twice with transport
buffer and total RNA was isolated using 1 mL TRIzol Reagent
(Invitrogen) per well according to the manufacturer's protocol. One
microgram of the resulting total RNA was reverse transcribed in the
presence and absence SuperScript™II Reverse Transcriptase
(Invitrogen) using oligo(dT)20 primers. Two microliters of the resulting
cDNA were used as a template for PCR reactions using GoTaq Green
Master Mix (Promega, Madison, WI) and gene specific primers
(Invitrogen) at 1 μM. Sequences for gene-specific primers and the
corresponding PCR cycling parameters are shown in Table 1.
((TABLE 1 here))

2.5. Data Analysis
Results of uptake assays are expressed as means ± SEM from
independent replicates. Uptake data were analyzed using GraphPad
Prism version 5.03 (GraphPad Software, San Diego, CA). Transport
data were analyzed by fitting untransformed data to appropriate
equations using iterative, least-squares curve-fitting techniques. IC50
values for inhibitors were determined by fitting the pooled data from
independent experiments to the one-site competition equation using
non-linear regression.
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3. Results
((FIGURE 1 here))

3.1. Expression of transporter mRNA in CGNs
RT-PCR was used to determine the expression of mRNA for
uptake1 (DAT, NET and SERT) and uptake2 (OCT1, OCT2, OCT3 and
PMAT) transporters in CGNs. All primer pairs were tested for their
ability to amplify the target genes from cDNAs obtained from tissues
known to express each of the transporters. All primer pairs were able
to amplify products of the expected size in cDNA from positive control
tissue: midbrain for OCT3, OCT2, PMAT, DAT, NET and SERT; and
kidney for OCT1(a and b) and OCT2; data not shown). As shown in
Figure 1, mRNAs for OCT1, OCT3, and PMAT were clearly detected in
CGNs, while mRNA for SERT was detected at very low levels, and
mRNAs for OCT2, DAT, and NET were not detected. Because the
results of the current OCT1 RT-PCR contradicted our previous results
[29], we repeated the OCT1 PCR using either the primer pair that we
used in the earlier publication (OCT1b), or the new primer pair
(OCT1a). Using the OCT1a primer pair, we detected OCT1 mRNA in
CGNs, as well as in forebrain, liver, kidney and lung. Using the OCT1b
primer pair, we failed to detect OCT1 mRNA in CGNs or in rat
forebrain, but did detect OCT1 mRNA in kidney, liver and lung tissue
(data not shown).
((FIGURE 2 here))
((FIGURE 3 here))

3.2. [3H]-MPP+ uptake assays
Previous studies demonstrated saturable accumulation of [3H]MPP+ by cultured CGNs, and presented evidence that this accumulation
was mediated by OCT3 (Shang et al, 2003). We tested the sensitivity
of CGN accumulation of [3H]-MPP+ to the potent uptake2 inhibitor
decynium-22, and to a variety of natural and synthetic corticosteroids.
Uptake of [3H]-MPP+ was inhibited by both decynium-22 and
corticosterone in a dose dependent manner, with decynium-22
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inhibiting a larger fraction of MPP+ accumulation than did
corticosterone (Figure 2, Table 2). Accumulation of [3H]-MPP+ was also
partially inhibited by other naturally occurring corticosteroids and their
metabolites, including aldosterone, cortisol, 11-deoxycorticosterone
(11-DOC), and cortisone (Figure 3-4, Table 2). These steroids inhibited
[3H]-MPP+ uptake with efficacies similar to that of corticosterone
(Table 2). 11-Dehydrocorticosterone had only a slight inhibitory effect
on [3H]-MPP+ uptake (Figure 4, Table 2). Synthetic corticosteroids
inhibited [3H]-MPP+ uptake with varying efficacies. Betamethasone
inhibited uptake with an efficacy similar to that of corticosterone, while
dexamethasone and prednisolone were less effective (Figure 5, Table
2). The glucocorticoid receptor antagonist RU38486 inhibited [3H]MPP+ uptake, but was less effective than corticosterone (Figure 5,Table
2). Decynium-22 inhibited a larger fraction of uptake than did any of
the steroids examined (Figure 2, Table 2).
((TABLE 2 here))

4. Discussion
This study is the most detailed characterization of the
corticosteroid sensitivity of uptake2-mediated transport, and the first in
CNS cells. The data from expression and functional studies indicate
that uptake2 is the primary monoamine transport system in CGNs, and
that, as in peripheral tissue, uptake2 activity in the CNS is broadly
sensitive to inhibition by both natural and synthetic corticosteroid
hormones. These data are consistent with the hypothesis that natural
and synthetic corticosteroids exert modulatory actions in the CNS via
inhibition of uptake2 -mediated clearance of monoamines, and that
inhibition of uptake2 -mediated monoamine clearance may underlie
some of the effects of these hormones on neuronal physiology and
behavior.
((FIGURE 4 here))
The data from RT-PCR studies indicate that [3H]-MPP+
accumulation by CGNs is mediated primarily by three uptake2
transporters: OCT1, OCT3 and PMAT. These data are consistent with
previous studies demonstrating expression of OCT3, OCT1 and PMAT
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protein or mRNA expression in the cerebellar granule layer [4, 14, 31].
However, our detection of OCT1 mRNA expression in CGNs is not
consistent with our previous report that OCT1 mRNA is not expressed
in these cells [29]. This discrepancy may be due to the use of different
primer sets in the two studies. In the present study, we used a primer
set (OCT1a) that targets the 3’ end of the OCT1 cDNA, whereas in the
previous study, we used a primer set (OCT1b) that targets a region in
the middle of the OCT1 cDNA. Both primer sets detected OCT1 mRNA
in cDNA from kidney, raising the possibility that kidney and brain OCT1
mRNAs represent alternatively spliced forms of the gene, as has been
reported for human OCT1 [32]. To address this discrepancy, we
performed parallel PCR using each of the OCT1 primer pairs to amplify
product from CGN and kidney cDNAs. Using the OCT1b primers (from
our earlier publication), we again detected OCT1 mRNA in kidney, but
not in CGN cDNA. Using the OCT1a primers, we detected OCT1 mRNA
in both kidney and CGN. These results suggest that the OCT1 mRNA
we detected in CGNs represents an alternatively spliced form of the
gene. Further studies are required to test this hypothesis.
The data from RT-PCR studies further demonstrate that CGNs do
not express DAT and NET, and that they express only very low levels
of SERT. These results are consistent with previous studies examining
DAT and SERT mRNA expression in CGNs [29, 33]. Our data on the
expression of these uptake1 transporters seem to contradict previous
studies demonstrating the expression of DAT, NET and SERT in the
cerebellar granule layer. However, these studies measured radioligand
binding in intact brain sections, or uptake of substrates by acutelyprepared synaptosomes [34-38]. Data obtained using these techniques
likely reflect transporters expressed on monoaminergic terminals in
the cerebellar granule layer [39-41], rather than specifically in CGNs.
Our data reflect transporter expression almost exclusively in CGNs.
((FIGURE 5 here))
Our functional studies are also consistent with a primary role of
uptake2 in CGN transport. Two well-characterized uptake2 inhibitors,
decynium-22 and corticosterone, each inhibited substantial fractions of
MPP+ uptake in the present studies. All of the transporters we detected
in CGNs are inhibited by decynium-22, though their sensitivities are
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not equivalent. OCT3 and PMAT are the most sensitive to decynium-22
inhibition (IC50 = 9-100 nM for OCT3, 100 nM for PMAT), while OCT1 is
significantly less sensitive (IC50 = 0.5-1μM) [13, 23, 42-44]. Some
reports have suggested that, at very high concentrations, decynium22 can inhibit NET and SERT [45, 46]. In the present studies,
decynium-22 inhibited approximately 80% of [3H]-MPP+ accumulation
with the same potency (IC50 = 3.4 nM) as reported in our previous
studies [29]. As the concentrations of decynium-22 used in the current
study (0.01 nM – 0.1 μM) did not reach the previously reported IC50s
for OCT1, the data suggest that the decynium-22-sensitive fraction of
MPP+ accumulation reported here is mediated primarily by PMAT and
OCT3, and that the remaining fraction of MPP+ accumulation is
mediated by OCT1, with a possible contribution of SERT.
While all of the uptake2 transporters expressed in CGNs are
inhibited by corticosterone, they differ greatly in their sensitivity. OCT3
is the most corticosterone-sensitive, followed by OCT1 and PMAT [3,
13, 16-18, 47]. The concentrations of corticosterone used in the
current study did not reach the previously-reported IC50s for inhibition
of OCT1 (150 μM) or PMAT (450 μM). Thus, the corticosteronesensitive MPP+ uptake (50-60% of total uptake) observed in the
present study is likely mediated primarily by OCT3, with the
corticosterone-insensitive fraction (40-50% of total uptake) mediated
by PMAT and OCT1. Given the high levels of PMAT mRNA we detected
in relation to OCT3, it is surprising that the corticosterone-insensitive
fraction of MPP+ accumulation in CGNs is not larger. This may be due
to differences in the efficiencies with which OCT3 and PMAT transport
MPP+. In support, recently published studies demonstrated that the
Vmax for OCT3-mediated MPP+ uptake is twofold higher than that of
PMAT [18].
Previous studies demonstrated that corticosterone-induced
inhibition of OCT3-mediated transport is a non-genomic, GRindependent phenomenon [7]. The present studies are consistent with
a non-genomic mechanism, in that inhibition of MPP+ uptake by all
tested corticosteroids was evident with only 5 minutes of steroid
exposure, and that the GR antagonist RU38486 also inhibited MPP+
accumulation. The IC50 for corticosterone inhibition of MPP+
accumulation reported in the present study (81 nM) is consistent with
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previous studies [3, 29], and is within the physiological range reported
for stress-induced corticosterone concentrations the rat brain [48, 49].
While each of the individual uptake2 transporters is inhibited by
corticosterone, their sensitivities to other corticosteroids have not been
thoroughly characterized. Early studies in peripheral tissues
demonstrated that a variety of natural corticosteroids inhibit uptake2
activity or enhance the actions of epinephrine [11, 12]. However, the
effects of corticosteroids other than corticosterone on individual
uptake2 transporters have been examined only for OCT3. Those
studies demonstrated that OCT3 is inhibited by budesonide,
methylprednisolone, and fluticasone [7, 28]. Our data indicate that
uptake2-mediated transport in the CNS is broadly sensitive to inhibition
by natural and synthetic corticosteroids. While it is likely that these
corticosteroids exert their effects at least in part by inhibiting OCT3,
further studies are required to determine the specific contributions of
each of the expressed transporters to corticosteroid-sensitive uptake.
The mineralocorticoids aldosterone and 11-DOC also inhibited
MPP accumulation by CGNs. This is consistent with previous studies,
which demonstrated that these two mineralocorticoids could inhibit the
clearance of epinephrine and norepinephrine, and potentiate their
actions in vascular or cardiac tissue [11, 12, 50, 51]. This is the first
study demonstrating mineralocorticoid-sensitive transport in CNS cells,
and suggests that mineralocorticoids also exert actions in the CNS by
inhibiting uptake2-mediated monoamine clearance. Interestingly, OCT3
knockout mice display alterations in salt intake that are comparable to
those exhibited by aldosterone-treated animals [15]. As OCT3 protein
and mRNA are expressed in brain regions involved in regulation of salt
intake, including circumventricular organs and medial amygdala, these
data raise the possibility that this particular uptake2 transporter
represents a target for mineralocorticoid action on ingestive behavior
[4, 15].
+

Comparison of the effects of corticosterone, 11-DOC and 11dehydrocorticosterone on MPP+ accumulation indicates that slight
differences in corticosteroid structure significantly alter potency and
efficacy of steroid-mediated inhibition of uptake2. These three steroids
differ in structure only at C11 of the steroid backbone. 11-
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Deoxycorticosterone, which differs from corticosterone only by the lack
of a hydroxyl group at C11, was a more potent and slightly more
effective inhibitor of MPP+ accumulation than was corticosterone,
suggesting that the lack of the C11 hydroxyl group may increase the
potency of 11-DOC at OCT3 and/or make it a more effective inhibitor
of PMAT and/or OCT1. 11-Dehydrocorticosterone, which contains a
keto- group at C11, was a much less effective inhibitor than either
corticosterone or 11-DOC. Further studies are necessary to determine
the effects of these steroids on individual uptake2 transporters.
The present studies are the first to demonstrate sensitivity of
uptake2 activity to dexamethasone, prednisolone, and betamethasone,
and to demonstrate that uptake2-mediated transport in the CNS is
sensitive to synthetic corticosteroids. These results are consistent with
studies demonstrating that OCT3-mediated monoamine transport in
bronchial smooth muscle cells is inhibited by budesonide, fluticasone
and methylprednisolone [7, 28]. Again, further studies are required to
determine the relative contributions of OCT3, OCT1 and PMAT to the
effects of each of the tested synthetic steroids. However, these studies
raise the interesting possibility that synthetic corticosteroids may
acutely and potently enhance monoaminergic neurotransmission in the
CNS, and that these actions may in part underlie previously described
acute effects of synthetic corticosteroid treatment on behavior in
humans [52-54].
Both natural and synthetic corticosteroids have powerful effects
on monoamine-regulated behaviors, [52-59, 59]. Accumulating
evidence suggests that uptake2 transporters may play important roles
in regulating monoaminergic neurotransmission in specific brain
regions [1, 3, 24, 25]. The present studies demonstrate that uptake2
represents an important target for corticosteroid action in the brain
and that inhibition of uptake2-mediated clearance of monoamines must
be taken into consideration when interpreting the results of acute
treatment with both natural and synthetic corticosteroid hormones.
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Figure 1. Expression of monoamine transporters in CGNs. RT-PCR was performed
using total RNA extracted from CGNs and primers specific to OCTs 1, 2, and 3, plasma
membrane monoamine transporter (PMAT), dopamine (DAT), norepinephrine (NET) or
serotonin reuptake transporter (SERT). PCR was performed on cDNA samples
generated in the presence (+) or absence (-) of reverse transcriptase. Only RT-PCR
that included reverse transcriptase (+) produced distinct bands for any of the
transporters. mRNAs for OCT1, OCT3 and PMAT were clearly detected, and a very
small amount of mRNA for SERT was detected, in CGNs.

Figure 2. Effects of Decynium-22 and corticosterone on CGN accumulation of [3H]MPP+. Cultured CGNs were incubated in uptake buffer containing the indicated
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concentrations of inhibitors for 5 min, after which 20 nM [3H]-MPP+ was added and
uptake was measured after 2 min. Decynium-22 (Δ) and corticosterone (●) inhibited
[3H]-MPP+ accumulation in a concentration-dependent manner. Error bars represent −
SE from n = 3 (decynium-22) or 8 (corticosterone) replicate wells.

Figure 3. Effects of corticosteroids on CGN accumulation of [3H]-MPP+. Cultured
CGNs were incubated in uptake buffer containing the indicated concentrations of
inhibitors for 5 min, after which 20 nM [3H]-MPP+ was added and uptake was
measured after 2 min. Aldosterone (о), cortisol (●) and cortisone (Δ) inhibited [3H]MPP+ accumulation in a concentration-dependent manner. Error bars represent − SE
from n = 3 (aldosterone, cortisone) or 4 (cortisol) replicate wells.

Figure 4. Effects of corticosterone and its metabolites on accumulation of [3H]MPP+ by CGNs. Cultured CGNs were incubated in uptake buffer containing the
indicated concentrations of steroids for 5 min, after which 20 nM [3H]-MPP+ was added
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and uptake was measured after 2 min. The data for corticosterone (●) are from Figure
2, presented here for comparison to the other steroids. Both 11-deoxycorticosterone
(о) and 11-dehydrocorticosterone (Δ) inhibited [3H]-MPP+ accumulation in a
concentration-dependent manner, though with different efficacies. Error bars
represent − SE from n = 3 (11-dehydrocorticosterone, 11-deoxycorticosterone) or 8
(corticosterone) independent wells.

Figure 5. Effects of synthetic corticosteroids on accumulation of [3H]-MPP+ by
CGNs. Cultured CGNs were incubated in uptake buffer containing the indicated
concentrations of steroids for 5 min, after which 20 nM [3H]-MPP+ was added and
uptake was measured after 2 min. A. Betamethasone (), prednisolone (●) and
RU38486 (о) dose-dependently inhibited [3H]-MPP+ accumulation. B. Dexamethasone
(●) dosedependently inhibited [3H]-MPP+ accumulation. Error bars represent − SE
from n = 3 (betamethasone, prednisolone, RU38486) wells or − SD from two
(dexamethasone) wells.
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